Quantification of folate metabolism using transient metabolic flux analysis. by Tedeschi, P.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/152636
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
RESEARCH Open Access
Quantification of folate metabolism using
transient metabolic flux analysis
Philip M Tedeschi1, Nadine Johnson-Farley1, Hongxia Lin1, Laura M Shelton2, Takushi Ooga3, Gillian Mackay4,
Niels Van Den Broek4, Joseph R Bertino1 and Alexei Vazquez1,4*
Abstract
Background: Systematic quantitative methodologies are needed to understand the heterogeneity of cell metabolism
across cell types in normal physiology, disease, and treatment. Metabolic flux analysis (MFA) can be used to infer steady
state fluxes, but it does not apply for transient dynamics. Kinetic flux profiling (KFP) can be used in the context of
transient dynamics, and it is the current gold standard. However, KFP requires measurements at several time points,
limiting its use in high-throughput applications.
Results: Here we propose transient MFA (tMFA) as a cost-effective methodology to quantify metabolic fluxes using
metabolomics and isotope tracing. tMFA exploits the time scale separation between the dynamics of different
metabolites to obtain mathematical equations relating metabolic fluxes to metabolite concentrations and isotope
fractions. We show that the isotope fractions of serine and glycine are at steady state 8 h after addition of a tracer,
while those of purines and glutathione are following a transient dynamics with an approximately constant turnover
rate per unit of metabolite, supporting the application of tMFA to the analysis of folate metabolism. Using tMFA, we
investigate the heterogeneity of folate metabolism and the response to the antifolate methotrexate in breast cancer
cells. Our analysis indicates that methotrexate not only inhibits purine synthesis but also induces an increase in the
AMP/ATP ratio, activation of AMP kinase (AMPK), and the inhibition of protein and glutathione synthesis. We also find
that in some cancer cells, the generation of one-carbon units from serine exceeds the biosynthetic demand.
Conclusions: This work validates tMFA as a cost-effective methodology to investigate cell metabolism. Using tMFA, we
have shown that the effects of treatment with the antifolate methotrexate extend beyond inhibition of purine synthesis
and propagate to other pathways in central metabolism.
Keywords: Metabolic flux analysis, Folate metabolism, Methotrexate
Background
Folates are carriers of one-carbon units that are trans-
ferred between metabolites [1] (Figure 1a). Purines, thy-
midylate, and methionine are one-carbon acceptors
required for cell proliferation. Serine, glycine, and formate
are one-carbon donors, and their relevance in specific cel-
lular systems is a current topic of intense research [2-5].
Serine can donate a one-carbon unit via the activity of
serine hydroxymethyl transferase (SHMT), and glycine
can donate one-carbon units via the glycine cleavage sys-
tem (GCS). Yet, in some cancer cells, serine is the major
one-carbon donor, they grow poorly in a serine-depleted
medium, and this serine dependence cannot be rescued by
supplementation of glycine in the culture medium [3].
Recent discoveries are pointing to new roles of folate
metabolism beyond the balance of one-carbon units
[4,6,7]. Theoretically, folate cycles can produce ATP via
the activity of reverse formyl-tetrahydrofolate synthase
(FTHFS). The ATP production is supported by flux bal-
ance modeling [6,7] and the induction of energy stress
upon inhibition of folate metabolism [7]. The folate cy-
cles can also produce NADPH via the activity of 5,10-
methylene-tretrahydrofolate dehydrogenase (MTHFD) and/
or 10-formyl-tetrahydrofolate dehydrogenase (FTHFD). The
NADPH production is supported by flux balance model-
ing [4,6,7], and it has been experimentally demonstrated
using 3H tracing [4]. When either reverse FTHFS or
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Figure 1 (See legend on next page.)
Tedeschi et al. Cancer & Metabolism  (2015) 3:6 Page 2 of 14
FTHFD is used to maintain the tetrahydrofolate (THF)
balance, the one-carbon does not contribute to biosyn-
thesis, but it is released as formate or CO2, respectively.
The heterogeneity of one-carbon metabolism can be in
part deduced from the patterns of gene expression across
human tumors [8]. These gene expression profiles can
constraint metabolic models to get predictions of meta-
bolic fluxes [9]. These models are however imprecise be-
cause there are different layers of regulation between gene
expression and reaction rates. Different experimental tech-
niques have been used to quantify one-carbon metabolism,
including metabolomics [10,11], 3H tracing [4,10,12,13],
and reporter assays [5]. Yet, we still lack a systematic
methodology for a comprehensive quantification of one-
carbon metabolism fluxes.
There are established approaches to estimate meta-
bolic fluxes, including metabolite consumption release
(CORE) profiles [14], metabolic flux analysis (MFA)
[15,16], and kinetic flux profiling (KFP) [17]. CORE pro-
files are used to estimate the exchange of metabolites be-
tween cells and the culture media. On top of CORE
profiles, MFA exploits the relationship between meta-
bolic fluxes and isotope fractions at steady state. How-
ever, not all metabolic fluxes can be inferred from the
CORE profiles and the steady state isotope fractions.
KFP allows for the estimation of additional fluxes know-
ing that the time scale for the transient dynamics of each
metabolite is determined by the ratio between the me-
tabolite concentration and its net flux of production/
consumption. However, KFP requires measurement of
isotope fractions at several time points, and therefore,
the estimation of additional fluxes comes at a higher
cost. Here we introduce a mixed approach where the
benefits of these methods are integrated.
Methods
tMFA
The basic equations of tMFA are derived and reported
in the Additional file 1.
Cells and culture media
MCF7, MDA-MB-231, and MDA-MB-468 breast cancer
cell lines were obtained from ATCC. Cells were maintained
in RPMI-1640 medium containing 10% fetal bovine serum
(FBS). RPMI-1640 medium containing 10% dialyzed FBS
was used for seeding and performing all experiments unless
otherwise noted. All cell culture medium and FBS were
purchased from Invitrogen (Carlsbad, CA, USA).
13C tracing (experiment 1, transient data, and TEPP-46)
Cell culture
6 × 105 MCF7 cells were plated into each well of six-well
tissue culture plates using RPMI-1640 medium containing
10% dialyzed FBS. The next day, culture medium was re-
moved and replaced with serine-free RPMI-1640 medium
containing 10% dialyzed FBS and 0.268 mM [U-13C]-L-
serine without any drug or with 100 nM methotrexate
(MTX) or 100 μM TEPP-46. Plates were incubated for 4,
8, and 16 h (MTX-treated cells) or 8 h (TEPP-46-treated
cells) and processed as described below.
Metabolite extraction
Immediately after the incubation period, adhered cells
were rapidly washed three times with chilled phosphate-
buffered saline (PBS). Intracellular metabolites were ex-
tracted, in triplicate, by adding a volume equivalent to 1 ×
106 cells/mL with extraction solution at 4°C (methanol,
acetonitrile, and water 5:3:2) and incubating the plate for
5 min at 4°C. The intracellular extract was collected and
mixed for 10 min at 4°C before being centrifuged at
16,100×g for 10 min at 4°C to precipitate the proteins.
The supernatants were transferred into HPLC vials and
stored at −80°C until liquid chromatography mass spec-
trometry (LC-MS) analysis.
LC-MS analysis
An Exactive Orbitrap mass spectrometer (Thermo Scien-
tific, Waltham, MA, USA) was used together with a
Thermo Scientific Accela HPLC system. The HPLC setup
consisted of a ZIC-pHILIC column (SeQuant, 150 × 2.1
mm, 5 μm, Merck KGaA, Darmstadt, Germany), with a
ZIC-pHILIC guard column (SeQuant, 20 × 2.1 mm) and
an initial mobile phase of 20% 20 mM ammonium car-
bonate, pH 9.4, and 80% acetonitrile. Cell extracts (5 μL)
were injected, and metabolites were separated over a 15-
min mobile phase gradient, decreasing the acetonitrile
content to 20%, at a flow rate of 200 μL/min and a column
temperature of 45°C. The total analysis time was 23 min.
(See figure on previous page.)
Figure 1 tMFA protocol and validation. (a) Simplified diagram of one-carbon metabolism. (b) Schematic representation of changes in isotope
fractions after addition of a tracer in the culture media at plating. The white bars represent the unlabeled fraction from the intracellular metabolite
present at plating, the cyan bar the unlabeled metabolite synthesized from unlabeled precursors and the red bar the labeled metabolite synthesized
from labeled precursors. f denotes the rate of synthesis and k the rate of turnover per unit of metabolite. (c) Changes in the isotope pools due to
inhibition of metabolite synthesis. (d) Sketch of the tMFA protocol. (e-h) Isotope fractions of serine and glycine in MCF7 cells, untreated or treated with
MTX (black, M+0; red, M+1; green, M+2, and blue, M+3). (i-l) Estimated turnover rate of purines and glutathione (GSH) in MCF7 cells, untreated or
treated with MTX (black lines, experiment 1, LC-MS quantification; circle, experiment 2, CE-MS quantification). The lines/points represent the average and
the error bars the standard deviation over three replicates. (m-p) Comparison between the predicted isotope fractions based on turnover estimates for Exp
2 (dashed line) and the isotope fractions measured in Exp 1 (solid line), for both purines and glutathione in untreated and MTX-treated cells.
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All metabolites were detected across a mass range of 75 to
1,000 m/z using the Exactive mass spectrometer at a reso-
lution of 25,000 (at 200 m/z), with electrospray ionization
(ESI) and polarity switching to enable both positive and
negative ions to be determined in the same run. Lock
masses were used, and the mass accuracy obtained for all
metabolites was below 5 ppm. Data were acquired with
Thermo Xcalibur software (Thermo Scientific, Waltham,
MA, USA).
Peak areas
The peak areas of different metabolites were determined
using Thermo TraceFinder software (Thermo Scientific,
Waltham, MA, USA) where metabolites were identified
by the exact mass of the singly charged ion and by
known retention time on the HPLC column. Commer-
cial standards of all metabolites detected had been ana-
lyzed previously on this LC-MS system with the pHILIC
column. The 13C-labeling patterns were determined by
measuring peak areas for the accurate mass of each iso-
topologue of many metabolites. Intracellular metabolites
were normalized to protein content of the cells, mea-
sured at the end of the experiment by the Lowry assay.
13C tracing (experiment 2, data across cell lines)
Cell culture
3 × 106 (MCF7), 3 × 106 (MDA-MB-468), or 4 × 106
(MDA-MB-231) cells were plated into 10-cm plates using
RPMI medium containing 10% dialyzed FBS. The next
day, culture medium was removed and replaced with
serine-free RPMI medium containing 10% dialyzed FBS
and 0.268 mM U-13C-serine (MCF7 or MDA-MB-231,
with or without 100 nMMTX) or 11.1 mM U-13C-glucose
(MDA-MB-468, with or without 100 nM MTX; MDA-
MB-231, with or without 2.5 μM atorvastatin). Plates were
incubated for 8 h and then harvested and processed as de-
scribed below.
Metabolite extraction
The culture medium was aspirated from the plates, and
cells were washed twice by 5% mannitol solution (10 mL
first and then 2 mL). The cells were then treated with
800 μL of methanol and left at rest for 30 s in order to
inactivate enzymes. Next, the cell extract was treated
with 550 μL of Milli-Q water containing internal stan-
dards (H3304-1002, Human Metabolome Technologies,
Inc., Tsuruoka, Japan) and left at rest for another 30 s.
The extract was obtained and centrifuged at 2,300×g and
4°C for 5 min, and then 800 μL of upper aqueous layer
was centrifugally filtered through a Millipore 5-kDa cut-
off filter at 9,100×g and 4°C for 120 min to remove
proteins. The filtrate was centrifugally concentrated and
re-suspended in 50 μL of Milli-Q water for capillary
electrophoresis mass spectrometry (CE-MS) analysis.
CE-MS
CE-time-of-flight mass spectrometry (TOFMS) was car-
ried out using an Agilent CE Capillary Electrophoresis
system equipped with an Agilent 6210 Time of Flight
mass spectrometer, Agilent 1100 isocratic HPLC pump,
Agilent G1603A CE-MS adapter kit, and Agilent G1607A
CE-ESI-MS sprayer kit (Agilent Technologies, Waldbronn,
Germany). The systems were controlled by Agilent
G2201AA ChemStation software version B.03.01 for CE
(Agilent Technologies, Waldbronn, Germany). The me-
tabolites were analyzed by using a fused silica capillary (50
μm i.d. × 80 cm total length), with commercial electro-
phoresis buffer (solution ID: H3301-1001 for cation
analysis and H3302-1021 for anion analysis, Human Me-
tabolome Technologies, Inc., Tsuruoka, Japan) as the elec-
trolyte. The sample was injected at a pressure of 50 mbar
for 10 s (approximately 10 nL) in cation analysis and 25 s
(approximately 25 nL) in anion analysis. The spectrometer
was scanned from m/z 50 to 1,000. Other conditions were
as described previously [18-20].
Peak areas
Peaks were extracted using automatic integration software
MasterHands (Keio University, Tsuruoka, Japan) in order to
obtain peak information including m/z, migration time
(MT) for CE-TOFMS measurement, and peak area. Signal
peaks corresponding to adduct ions and other product ions
of known metabolites were excluded, and the remaining
peaks were annotated with putative metabolites and their
isotopic ions from the HMT metabolite database based on
their MTs and m/z values determined by TOFMS. The
tolerance range for the peak annotation was configured
at ±0.5 min for MTand ±30 ppm for m/z. In addition, peak
areas were normalized against those of the internal stan-
dards, and then the resultant relative area values were
further normalized by sample amount.
TEPP-46 growth inhibition
5 × 103 cells per well were plated in 96-well plates in
Roswell Park Memorial Institute medium (RPMI)-1640
media containing 10% dialyzed FBS. The next day, medium
was removed and replaced with fresh medium containing
varying concentrations of MTX with and without 100 μM
TEPP-46. Plates were incubated for 72 h. Cell viability was
assayed using the Cell Titer 96 Aqueous One Solution
(MTS) assay, performed according to the manufacturers’
protocol (Promega, Madison, WI, USA).
Protein and phosphoprotein expression
Twenty-four hours before methotrexate treatment, 3 ×
106 MCF7, MDA-MB-468, or MDA-MB-231 cells were
seeded in 10-cm plates in RPMI medium supplemented
with 10% dialyzed FBS and incubated overnight at 37°C
in an incubator with 5% CO2. At the time of treatment,
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culture medium was removed and replaced with fresh
medium or fresh medium containing 100 nM MTX and
placed into a 37°C incubator with 5% CO2. At the sam-
pling time points, culture medium was removed and
cells were rinsed with PBS (Gibco, Grand Island, NY,
USA) and scraped into microcentrifuge tubes. After brief
centrifugation, cell pellets were lysed in RIPA buffer con-
taining a commercial protease inhibitor mix (Roche,
Nutley, NJ, USA) and phosphatase inhibitor (50 mM so-
dium fluoride, 10 mM sodium orthovanadate). After pro-
tein quantification by the Bradford protein assay (Bio-Rad
Laboratories, Hercules, CA, USA), proteins were resolved
by 10% SDS-PAGE and transferred onto a nitrocellulose
membrane (Bio-Rad Laboratories, Hercules, CA, USA).
After blocking the membrane with 5% nonfat dry milk
prepared in tris-buffered saline + 0.1% Tween-20, the
membrane was incubated with the desired primary anti-
body according to the manufacturer’s directions at 4°C
overnight. The membrane was washed in tris-buffered sa-
line + 0.1% Tween-20 and incubated for 2 h at room
temperature with the appropriate peroxidase-conjugated
secondary antibody. Bands were visualized using an en-
hanced chemiluminescence kit (Pierce, Thermo Fisher
Scientific, Rockford, IL, USA). Anti-AMP-activated pro-
tein kinase (AMPK), anti-Thr172 pAMPK, anti-acetyl-
CoA-carboxylase (ACC), anti-Ser79 ACC, and anti-rabbit
secondary were purchased from Cell Signaling Technology
(Danvers, MA, USA). Anti-glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was purchased from Millipore
(Billerica, MA, USA), and anti-mouse secondary was
purchased from Santa Cruz Biotechnologies (Dallas, TX,
USA).
Metabolic flux estimation errors
The errors in the flux estimations could be only due to the
fitting of the tMFA model equations for purines (Additional
file 1, equations 2.1.1 and 2.1.2) to the observed data.
In all conditions analyzed, we obtained chi-squared test
P values for the fitting that are orders of magnitude below
0.05. Beyond that, the number of parameters equals the
number of measurements required to solve the tMFA
equations. There are no significant fitting errors compared
to the variations we observe between replicates.
Statistical analyses
All the metabolic flux estimations were carried out using
input data for one technical replicate at the time. The
metabolite concentrations, isotope fractions, and esti-
mated fluxes reported in Figures 1, 2, 3, 4, 5, 6, and 7
represent the average and standard deviation (error bars)
across three technical replicates. All reported P values
were determined by comparing the three technical repli-
cates from untreated and three technical replicates from
treated cells using ANOVA.
Results and discussion
Transient metabolic flux analysis
After the addition of a tracer to a cell culture, an intra-
cellular metabolite pool can be divided into unlabeled
metabolite remaining from the initial pool (residual) and
Figure 2 Inhibition of purine synthesis. (a) Purine concentration (Cpur) 8 h after plating in untreated (open bars) and MTX-treated (filled bars) cells:
MCF7 (7), MDA-MB-468 (468), and MDA-MB-231 (231). (b) Pyrimidine concentrations at the same time point. (c) Fraction of unlabeled purines.
(d) Estimated purine synthesis rate. (e) Estimated purine turnover rate per unit of purines. (f) Balance between the purine synthesis (fpur) and
consumption (gpur = kpurCpur) rates. The white and blue bars represent the rate of purine synthesis (white, untreated; blue, MTX-treated), and the
dashed black and dashed blue bars represent the rate of purines consumption (black, untreated; blue, MTX-treated). The symbol *X denotes a
difference between untreated and MTX-treated with a statistical significance less than 5 × 10−X.
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unlabeled/labeled metabolite synthesized during the
course of the experiment (Figure 1b). We can chose to
interrogate metabolites at an intermediate time where
some metabolites are at steady state (no residual) and
others are still following their transient dynamics. In this
context, we can use a hybrid approach between MFA
and KFP to infer the metabolic fluxes (Additional file 1).
The resulting mathematical equations have a structure
similar to those derived in MFA [15], except for a par-
ameter ε quantifying the transient amount of residual.
Thus, we name this methodology transient MFA (tMFA).
tMFA can be used to investigate the effect of interven-
tions on metabolism (Figure 1c). By comparing the esti-
mated synthesis rate between untreated and treated
conditions, we can quantify the inhibition of metabolite
synthesis.
The experimental protocol implementing tMFA is
sketched in Figure 1d. Media samples are taken at plat-
ing (t = 0) and at sampling (t = T) times to estimate ex-
change rates between the media and cells. Cell samples
are taken at the sampling time to quantify intracellular
metabolite concentrations and isotope fractions. The
quantification of media and cell metabolite concentrations
and isotope fractions can be done using metabolomic
techniques. The tMFA equations are then used to infer
the metabolic fluxes from these measurements. On its
current implementation, tMFA is based on two major as-
sumptions (i) that the isotope fractions of steady state me-
tabolites are approximately constant in time and (ii) that
the turnover rate of transient metabolites is approximately
constant in time.
Here we use tMFA to quantify folate metabolism
fluxes (Figure 1a) and their response to treatment with
the antifolate MTX, a well-known inhibitor of purine
synthesis [12]. To interrogate folate metabolism using
tMFA, we first validated the tMFA approximations. In a
first experiment (Exp 1), we performed [U-13C]-L-serine
tracing in MCF7 cells at different time points (4, 8, and
16 h after addition of the tracer) and quantified the 13C
fractions using LC-MS. When treating cells with MTX,
the drug was added at the 0-h time point. In a second
experiment (Exp 2), we performed [U-13C]-L-serine tra-
cing in MCF7 cells at 8 h after addition of the tracer and
quantified the 13C fractions using CE-MS. To take into
account the potential variations in cell size, we normal-
ized the metabolite concentrations and fluxes by the cell
volume. All concentrations are reported in mol/L cell
(molar, M) and the fluxes in mol/h/L cell (M/h).
Figure 3 Energy stress and inhibition of protein synthesis. (a) AMP to ATP ratio in untreated cells (open white bars) and cells treated with MTX
(filled blue bars). (b) ZMP levels. Not detected in untreated MCF7 cells. (c) Protein and phosphoprotein levels at different times after MTX
treatment. (d,e) Ratio of phosphorylated to total protein levels using different scales for the Y-axis. (f) Protein synthesis rate estimated from the
uptake of essential amino acids. Bars represent the average and error bars the standard deviation over three replicates. The symbol *X denotes a
difference between untreated and MTX-treated with a statistical significance less than 5 × 10−X.
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Intracellular serine has a concentration (C) in the mM
range and the net flux of serine production/consumption
(f ) is in the mM/h range, resulting in a typical transient
time scale (τ~C/f ) of about 1 h. Therefore, serine could
be treated as a steady state metabolite at the 8-h sam-
pling point. The measured intracellular 13C fractions are
indeed almost constant in time from 4 to 16 h in both
untreated (Figure 1e) and MTX-treated (Figure 1f )
MCF7 cells. There is a small but appreciable decay of
the M+3 serine fraction. This is most likely due to a
leaking of serine from cells to the media, in spite of a
net serine uptake. This leaking can be deduced from the
measurement of an about 10% M+0 fraction of serine in
the culture media at 8 h, which originally contained only
M+3 serine. This unlabeled serine comes from de novo
serine synthesis from glucose. The unlabeled serine pool
will increase in time while M+3 serine pool is fixed to
the amount originally in the media. Therefore, [U-13C]-
L-serine tracing experiments beyond 8 h will be forced
to take this leaking into consideration.
Similar to serine, intracellular glycine has a concentra-
tion in the mM range and the net flux of glycine produc-
tion/consumption is in the mM/h range, resulting on a
typical transient time scale of about 1 h. Therefore, glycine
could be also treated as a steady state metabolite at the
8-h sampling point. The measured 13C glycine fractions
are at steady state between 8 and 16 h in both untreated
(Figure 1g) and MTX-treated MCF7 cells (Figure 1h).
The purine intracellular pool has also a concentration
in the mM range, but the net flux of purine production/
consumption is in the 0.1-mM range (see estimates
below), resulting on a typical transient time scale of
about 10 h. Therefore, purines should be treated as tran-
sient metabolites when profiling cells around 8 h. In the
current implementation of tMFA, we assume that transi-
ent metabolites have a constant turnover rate per unit of
metabolite (k), defined as the net rate of metabolite con-
sumption divided by the metabolite concentration. The
turnover rate of purines (kpur) at a given time point can
be estimated from the purine 13C fractions measured at
that time point (Additional file 1). In untreated MCF7
cells, the estimated kpur is approximately constant be-
tween 4 and 8 h but drops at 16 h (Figure 1i). In MCF7
cells treated with MTX kpur decays gradually (Figure 1j),
but the difference between the value at 4 and 8 h is
small and comparable to the variation between the two
independent experiments. Based on this data, we con-
clude that kpur is approximately constant between 4 and
8 h and we can apply tMFA to purines within this time
window.
The concentration of glutathione (GSH) is around 6
mM while its production/consumption rate is 0.6 mM/h
Figure 4 Glutathione balance. (a) GSH synthesis and turnover. (b) GSH concentration (CGSH) 8 h after plating in untreated (open bars) and
MTX-treated (filled bars) cells. (c) Fraction of unlabeled GSH. (d) Estimated GSH synthesis rate. (e) Estimated GSH turnover rate. (f) Estimated GSH
consumption rate (gGSH = kGSHCGSH). Bars represent the average and error bars the standard deviation over three replicates. The symbol *X
denotes a difference between untreated and MTX-treated with a statistical significance less than 5 × 10−X.
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(as reported below), resulting on a typical transient time
scale of about 10 h. Therefore, glutathione should also
be treated as transient metabolite when profiling cells
around 8 h, and we should validate the tMFA assump-
tion of a constant glutathione turnover rate (kGSH). kGSH
can be estimated at a given time point from the GSH-
labeling fractions at that time point. We observed that
the estimated kGSH is approximately constant between 4
and 16 h in untreated (Figure 1k) and MTX-treated
(Figure 1l) MCF7 cells. Based on this data, we conclude
that kGSH is approximately constant between 4 and 16 h
and we can apply tMFA to glutathione within this time
window.
The analysis of the transient 13C data indicates 8 h as
an optimal choice to apply tMFA. At earlier times, the
13C fractions of glycine are still following a transient dy-
namics. At later times, the assumption of a constant
purine turnover rate does not hold and the serine 13C
fractions depart from steady state. To further validate
the choice of 8 h as an optimal sampling point, we esti-
mated the purine and glutathione turnover rates using
the 8-h data generated in Exp 2. Then we made predic-
tions for the time profiles of the purine and glutathione
unlabeled fractions, assuming a constant turnover rate
equals to the estimated value. In the case of purines, the
predicted time profiles are in good agreement with those
Figure 5 Serine balance. (a) Serine synthesis and consumption. Abbreviations: glc, glucose; ser, serine; gly, glycine; SHMT-, reverse SHMT.
(b) Serine concentration 8 h after plating in untreated (open bars) and MTX-treated (filled bars) cells. (c) Serine uptake rate. (d) Serine consumption by
protein synthesis. (e) Serine synthesis rate from glucose. (f) 3-phosphoglycerate (3PG) concentration. (g-i) Growth inhibition by co-treatment with MTX
(1 to 100 nM) and the PKM2 activator TEPP-46 (100 μM). Bars represent the average and error bars the standard deviation over three replicates. The
symbol *X denotes a difference between untreated and MTX-treated with a statistical significance less than 5 × 10−X.
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measured in Exp 1 at 4 and 8 h in both untreated and
treated cells (Figure 1m,n). However, deviations are ob-
served at the 16-h time point. In the case of glutathione,
the predicted time profiles are in good agreement with
those measured in Exp 1 at all the time points collected
in both untreated and treated cells (Figure 1o,p). This
validation not only supports the use of 8 h as an optimal
sampling point but also demonstrates the stability of the
estimates across independent experiments. Furthermore,
since the samples collected in Exp 1 and Exp 2 were an-
alyzed with LC-MS and CE-MS, respectively, this valid-
ation also demonstrates the stability of our estimates
across MS platforms. Finally, we profiled MDA-MB-231
cells using two different tracers, [U-13C]-L-serine and
[U-13C]-D-glucose, allowing us to compare the reliability
of tMFA estimates across tracers. The turnover rate esti-
mations for purines and glutathione using either tracer
and in good agreement, demonstrating that tMFA is
stable across the tracers (Additional file 1: Figure S1).
In the following, we analyze folate metabolism fluxes
using targeted metabolomics and 13C tracing in MCF7
and other breast cancer cell lines. Based on the analysis
above, we profiled cells 8 h after addition of the 13C
tracer. The cell lines MCF7, MDA-MB-468, and MDA-
MB-231 were selected to represent high (IC50 = 5 nM),
medium (60 nM), and low (1,000 nM) sensitivity to
Figure 6 Glycine accumulation. (a) Glycine synthesis and consumption. Abbreviations: SHMT+, forward SHMT; GCS-, reverse GCS; mlthf, 5,10-
methylene-tetrahydrofolate. (b) Glycine concentration 8 h after plating in untreated (open bars) and MTX-treated (filled bars) cells. (c) Estimated
glycine exchange rate after corrected for GSH turnover. Positive values indicate uptake, and negative values release. (d) Glycine consumption for
protein synthesis. (e) Net SHMT rate (forward minus backward). (f) Forward SHMT rate. (g) Backward SHMT rate. (h) Glycine production from
unknown sources. (i) Exchange rate of choline. Positive values indicate uptake and negative values release. Bars represent the average and error
bars the standard deviation over three replicates. The symbol *X denotes a difference between untreated and MTX-treated with a statistical
significance less than 5 × 10−X.
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MTX treatment, respectively. We chose a MTX concen-
tration of 100 nM, above the IC50 for the most sensitive
cell line MCF7 but below the IC50 for the most insensi-
tive cell line MDA-MB-231. Unless otherwise specified,
the MCF7 and MDA-231 cell lines were profiled using
[U-13C]-L-serine and the MDA-MB-468 cell line using
[U-13C]-D-glucose as the tracer, in both cases resulting
in partial labeling of the metabolites of interest. We
choose [U-13C]-D-glucose for the MDA-MB-468 cell
line based on a previous report indicating that these cell
lines do not uptake serine [3], although these cells did
uptake serine in our culture conditions. All concentra-
tions are reported in mol/L cell (molar, M) and the
fluxes in mol/h/L cell (M/h).
Inhibition of purine synthesis
Upon treatment with MTX, we observed a twofold de-
crease of the purine concentration in MCF7 and MDA-
MB-468 cells but to a lesser extent in MDA-MB-231
cells (Figure 2a). As a control, the concentration of py-
rimidines remains practically unchanged in the three cell
lines (Figure 2b). We also observed a fourfold increase
in the unlabeled purine fraction in MCF7 and MDA-
MB-468 cells (Figure 2c), which could be the outcome
of inhibition of purine synthesis from labeled precursors.
Modeling purines as a transient metabolite, we estimated
their synthesis and turnover rates. There is about a
tenfold decrease in the rate of purine synthesis in MCF7
(P = 1.4 × 10−4) and MDA-MB-468 (P < 1.5 × 10−7) but
just a slight (less than twofold, P = 0.20) decrease for
MDA-MB-231 (Figure 2d). In the MCF7 cells, the purine
turnover per unit of purine (kpur) is not affected by MTX
treatment and there is just a slight increase in the MDA-
MB-468 and MDA-MB-231 cells (Figure 2e). Taken to-
gether, these data indicate that the reduction of the purine
concentration at 8 h is the result of inhibition of purine
synthesis with no change in the purine turnover rate.
In untreated cells, we would expect a steady state
where the purine production rate (fpur) is balanced by
the purine consumption rate (gpur), the latter being equal
to the purine turnover per unit of purine times the pur-
ine concentration (gpur = kpurCpur). Indeed, in untreated
cells, the tMFA estimates of fpur and gpur are approxi-
mately equal independently of the cell line (Figure 2f ).
In contrast, the purine consumption rate exceeds its
production rate in the MCF7 and MDA-MB-468 cells
following MTX treatment (Figure 2f ), consistent with
the drop in the purine concentration (Figure 2a).
Energy stress
Although the concentration of purine nucleotides decreases
following MTX treatment (Figure 2a and Additional
file 1: Figure S2), the changes are relatively different for
each nucleotide. We observe a significant increase in the
AMP/ATP ratio in the MCF7 and MDA-MB-468 cells
(Figure 3a), while the ADP/ATP ratio remains approxi-
mately constant (Additional file 1: Figure S2d). We also
observe a significant increase in the ZMP levels in MCF7
and MDA-MB-468 cells (Figure 3b). Increases of both the
AMP/ATP ratio and ZMP are signals that stimulate the
Figure 7 THF balance. (a) Reactions where a one-carbon unit is incorporated into (red) or released from (blue) folates. Abbreviations: thf,
tetrahydrofolate; mlthf, 5,10-methylene-thf; fthf, 10-formyl-thf; met, methionine; dTMP, thymidylate. (b) Rate of one-carbon transfer from mlthf to
methionine. (c) Backward rate of glycine cleavage. It could not be estimated in MDA-MB-468 because the glycine M+1 fraction was close to the
detection limit. (d) Formate released by the cholesterol synthesis pathway. Abbreviations: 44mctr, 4,4-dimethyl-5-α-cholesta-8,14,24-trien-3β-ol; for,
formate. (e) Purine isotope fractions in untreated (white boxes) and atorvastatin-treated (red boxes) MDA-MB-231 cells. (f) Difference between
one-carbon production by SHMT and one-carbon consumption by purine synthesis. Bars represent the average and error bars the standard deviation
over three replicates. The symbol *X denotes a difference between untreated and MTX-treated with a statistical significance less than 5 × 10−X.
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AMP kinase (AMPK) [21]. Indeed, following MTX treat-
ment, we observe an increase in the phosphorylation of
AMPK (pAMPK) relative to the AMK level in the MTX
sensitive MCF7 and MDA-MB-231 cell lines but not in
MDA-MB-231 (Figure 3c,d). In the MCF7 and MDA-MB-
468 cell lines, the increase in the pAMPK/AMPK ratio is
followed by an increase in the phosphorylation of the
AMPK target acetyl CoA carboxylase (ACC) (Figure 3c,d).
In the MDA-MB-231 cell line, there is also an increase in
ACC phosphorylation (Figure 3e). However, since there is
no trend in the pAMPK/AMPK ratio, we conclude that in
MDA-MB-231 cells, the increased ACC phosphorylation
is due to an AMPK-independent mechanism. We also no-
tice that the level of phosphorylation of both AMPK and
ACC is overall higher in MDA-MB-231 relative to MCF7
and MDA-MB-468, but this difference is observed already
in the absence of MTX treatment (Figure 3e, 0-h time
point). Thus, MTX treatment causes energy stress only in
the MTX sensitive cell lines MCF7 and MDA-MB-468.
Protein synthesis requires a high rate of ATP turnover,
and therefore, we hypothesized that MTX treatment
should indirectly inhibit protein synthesis. To estimate
the rate of protein synthesis, we used the uptake rate of
essential amino acids as a surrogate [22]. We have previ-
ously shown that the protein synthesis rate estimated by
this approach is proportional to the protein synthesis
rate estimated from the rate of 3H-leucine incorporation
into protein [22]. Following MTX treatment, there is a
significant decrease in the protein synthesis rate in MCF7
cells (P = 0.03, Figure 3f), a similar trend in MDA-MB-
468 cells (P = 0.63, Figure 3f), and no change in MDA-
MB-231 cells (P = 0.68, Figure 3f).
The synthesis of GSH is energy dependent (Figure 4a),
and it could also be inhibited by the energy stress caused
by MTX treatment. Upon MTX treatment, the GSH
concentration decreases significantly in the two sensitive
cell lines (P = 0.004, MCF7; P = 0.035, MDA-MB-468)
(Figure 4b). The fraction of unlabeled GSH increases
significantly in MCF7 (P = 0.0009) and MDA-MB-468
(P = 0.005) cells treated with MTX, but not in MDA-
MB-231 cells (P = 0.12) (Figure 4c). The increase in the
GSH unlabeled fraction may result from the inhibition
of GSH synthesis form labeled precursors. Modeling
GSH as a transient metabolite, we estimated the GSH
synthesis and turnover rates. Following MTX treatment,
there is a significant decrease in the glutathione synthe-
sis rate in MCF7 (P = 0.022) but no significant change in
MDA-MB-468 (P = 0.55) or MDA-MB-231 (P = 0.67)
cells (Figure 4d). The glutathione turnover rate increases
in the MCF7 (P = 0.024) and MDA-MB-468 (P = 0.00046)
cells treated with MTX, but it does not change signifi-
cantly in MDA-MB-231 (P = 0.49) cells (Figure 4e). How-
ever, in MCF7 cells, the increase in glutathione turnover
(measured per unit of glutathione) is balanced by a
decrease in the glutathione concentration (Figure 4b),
resulting in no significant change in the net glutathione
consumption rate (gGSH = kGSHCGSH, Figure 4f). In con-
trast, in MDA-MB-468 cells, where the glutathione con-
centration does not change (Figure 4b), the decrease in
turnover rate results in a significant increase (P = 0.00046)
in the net glutathione consumption rate (Figure 4f).
Taken together, these data indicate that MTX treat-
ment causes energy stress and inhibition of protein and
glutathione synthesis, in a degree proportional to the
growth inhibition sensitivity to MTX.
Induction of serine synthesis
Serine is a source of one-carbon units, and its balance
may be perturbed by MTX treatment. Serine can be
imported from the media, synthesized from glucose, or
derived from glycine via the reverse activity of SHMT
(Figure 5a). There is no significant difference in the
serine concentration of treated relative to untreated cells
for any of the three cell lines (Figure 5b). The uptake of
serine from the media decreases upon MTX treatment
(Figure 5c) in a degree proportional to the decrease in the
serine consumption rate for protein synthesis (Figure 5d).
In contrast, we observe a significant increase of serine
synthesis from glucose in MCF7 cells treated with MTX
(P = 0.03), but not a significant increase in MDA-MB-468
(P = 0.78) or MDA-MB-231 (P = 0.064) cells (Figure 5e).
The induction of serine synthesis is consistent with an
increase of the 3-phosphoglycerate (3PG) concentration
(P = 0.1, MCF7; P = 0.037; MDA-MB-468; P = 0.028,
MDA-MB-231; Figure 5f), the branching point from gly-
colysis to serine synthesis.
To investigate the contribution of serine synthesis in-
duction to growth inhibition by MTX, we modulated the
activity of PKM2. PKM2 is an isoform of pyruvate kinase
that is often overexpressed in cancer cells [23]. PKM2
can be found in an active tetramer or in an inactive
dimer form. This feature allows cells to favor either
pyruvate production (active tetramer) or production of
precursor metabolites such as 3PG (inactive dimer).
Using an allosteric activator of PKM2 that favors the
tetramer conformation (TEPP-46) [24], we investigated
if favoring production of pyruvate instead of 3PG would
have an effect on the response to MTX. Treatment of
MCF7 cells with 100 μM TEPP-46 resulted in a decrease
in the serine levels and an increase in the pyruvate levels
(Additional file 1: Figure S6), indicating that indeed
TEPP-46 activates glycolysis and inhibits serine synthe-
sis. However, there is no significant change in the
growth inhibitory activity of MTX upon co-treatment
with the PKM2 activator (Figure 5g,h,i). For MDA-MB-
231 cells, we observe a significant growth inhibition
when adding TEPP-46, but this effect is independent of
the MTX concentration (Figure 5i). These data indicate
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that MTX treatment can induce the synthesis of serine
from glucose, but this change does not contribute to the
growth inhibitory activity of MTX.
Accumulation of glycine
The inhibition of purine synthesis can perturb the bal-
ance of the purine precursor glycine. Glycine can be
imported from the media and derived from serine via
the SHMT forward activity (SHMT+), from GSH turn-
over, and other unaccounted sources (Figure 6a). The
intracellular glycine concentration increases about two-
fold in MCF7 and MDA-MB-468 cells treated with
MTX (Figure 6b). After correcting for the GSH turnover,
we observe a net glycine uptake from the media for the
three cell lines (Figure 6c). Similar to the serine uptake
rate, the glycine uptake rate decreases upon MTX treat-
ment in a degree proportional to the decrease in the gly-
cine consumption rate for protein synthesis (Figure 6d).
The net rate of serine to glycine conversion decreases
significantly in MCF7 cells (P = 0.0091), but it does not
change significantly for MDA-MB-468 (P = 0.86) and
MDA-MB-231 (P = 0.68) cells (Figure 6e). We note
however that in both sensitive MCF7 and MDA-MB-468
cells, the forward and backward rate of serine to glycine
conversion decreases (Figure 6f,g). This can be explained
by a decrease in the concentration of both THF (favoring
the forward reaction) and of 5,10-methenyl-THF (favoring
the backward reaction) following MTX treatment [10].
We also estimate the existence of an unknown source
of glycine with a variable production rate depending on
the cell line and treatment (Figure 6h). The basal rate of
glycine production from the unknown source is negli-
gible in MCF7 cells but increases upon MTX treatment
(Figure 6h). The other two cell lines have a significant
level of glycine production from unknown sources, and
this does not change significantly when treated with
MTX. Glycine can be derived from choline, and there-
fore, choline is a candidate for the unknown source of
glycine. In untreated MDA-MB-468 cells, the glycine
production rate from the unknown source (Figure 6h)
exceeds the rate of choline uptake (Figure 6i). After
MTX treatment, choline is actually released to the media
in MCF7 and MDA-MB-468 cells (Figure 6i). Therefore,
choline does not account for glycine production from
the unknown source in MCF7 and MDA-MB-468 cells.
In MDA-MB-231 cells, glycine production rate from the
unknown source is small (Figure 6h) and about the same
magnitude of choline uptake rate (Figure 6i).
Balance of one-carbon units
Next, we focused on the balance between reactions do-
nating/accepting one-carbon units. In addition to pu-
rines, one-carbon units can be donated to methionine
and thymidylate (Figure 7a). We applied FBA to estimate
the transfer rate of one-carbon units to methionine. The
obtained values are below 0.03 mM/h (Figure 7b), ten-
fold lower than the purine synthesis rate (Figure 2d).
The rate of thymidylate synthesis can be estimated based
on the cells doubling time, DNA content, and thymine
abundance in DNA. We obtain a thymidylate synthesis
rate of about 0.02 mM/h, again tenfold lower than the
purine synthesis rate (Figure 2d). Therefore, methionine
and thymidylate synthesis rates are not major consumers
of one-carbon units relative to purine synthesis.
We have also investigated other sources of one-carbon
units besides serine. Glycine can donate a one-carbon
unit via the GCS (Figure 1a). Based on the M+1 isotope
fraction of glycine, we estimate the reverse glycine cleav-
age rate to be in the 0.04 to 0.08 mM/h range (Figure 7c).
Although we cannot exclude that the forward rate may
over exceed the backward rate, the reversibility of the
GCS together with the lack of an appreciable backward
rate of glycine cleavage indicates that the GCS is not a
major source of one-carbon units in these cells.
Cholesterol synthesis is another potential source of
one-carbon units. In an intermediate step of this path-
way, a one-carbon from lanosterol is released as formate
(Figure 7d). We have shown that cell lines that are
highly sensitive to atorvastatin (including MDA-MB-
231) depend on de novo cholesterol synthesis for prolif-
eration [25]. To sort out the potential contribution of
one-carbon units by cholesterol synthesis, we analyzed
[U-13C]-D-glucose tracing data from MDA-MB-231
cells, untreated or treated with the cholesterol synthesis
inhibitor atorvastatin. We observe significant labeling of
citrate as expected from labeling of AcCoA from [U-13C]-
D-glucose (Additional file 1: Figure S7). The one-carbon
released as formate comes from AcCoA, and it should
have a significant M+1 fraction that would be reflected in
purines. However, there is no significant change in the
purine isotope fractions between atorvastatin treated and
untreated cells (P = 0.33, Figure 7e). Therefore, the for-
mate released by the cholesterol synthesis pathway is not
a significant source of one-carbon units.
Finally, we compared the net SHMT rate (generating a
one-carbon unit from serine) and the rate of purine syn-
thesis (consuming 2 one-carbon units per purine). In
MCF7 and MDA-MB-231 untreated and all treated cell
lines, the SHMT rate exceeds the one-carbon require-
ments for purine synthesis (Figure 7f ). In these cells,
there are additional reactions releasing one-carbon units.
One candidate is the reverse activity of FTHFS releasing
the one-carbon as formate and producing ATP [6,7]. An-
other candidate is the activity of FTHFD releasing the
one-carbon as CO2 and producing NADPH [4]. While
our current implementation of tMFA does not allow us
to resolve these two contributions, it shows that in
MCF7 and MDA-MB-231 cells, there is an excess
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production of one-carbon units from serine that is not
accounted for by biosynthetic processes. In contrast, in
untreated MDA-MB-468 cells, the SHMT rate is about
the rate of one-carbon requirements for purine synthesis
(Figure 7f ).
Unaccounted contributions
All metabolic flux analysis methodologies, including our
tMFA implementation, are limited to the biochemical
pathways build in into the calculations. To quantify con-
tributions not accounted by the model, we made a bal-
ance of the production and consumption of each
metabolite. As shown in the previous section, there is an
excess production of one-carbon units above the re-
quirements for purine synthesis. For serine, the uptake
and synthesis from glucose exceeds the consumption
rate from serine conversion to glycine and incorporation
into protein, in an amount between one and two times
the serine demand for protein synthesis (Figure 8a).
Most likely, this excess production is consumed in the
synthesis of cystathionine, phosphatidylserine, and sphin-
ganine. However, the determination of those fluxes is be-
yond the focus of this work on folate metabolism. For
glycine, we have the reported production from the un-
known source (Figure 6h), which takes values between half
and about the glycine demand for protein synthesis
(Figure 8b). For methionine, we have shown above that
there is no appreciable synthesis of methionine in the
three breast cancer cell lines analyzed (Figure 7b). The
methionine uptake approximately matches its demand for
protein synthesis in MCF7 (untreated and MTX-treated)
and MDA-MB-231 untreated cells (Figure 8c). In contrast,
methionine is imported in excess of its demand for pro-
tein synthesis in MDA-MB-468 (untreated and MTX-
treated) and MTX-treated MDA-MB-231 cells (Figure 8c),
in an amount between 25% and 50% of the demand
for protein synthesis. Most likely, the excess methio-
nine uptake is consumed in the production of S-
adenosylmethionine, which provides the methyl group
for methylation. However, the determination of this flux is
beyond the focus of this work on folate metabolism.
Conclusions
tMFA is an extension of MFA incorporating transient
isotope labeling data and taking advantage of a key fea-
ture of cell metabolism: the separation of time scales. By
choosing to profile intracellular metabolites at an inter-
mediate time point, we can divide metabolites into
steady state and transient metabolites. In the context of
folate metabolism, this includes the rate of purine and
glutathione synthesis. Although tMFA takes advantage
of transient data, it should not be confused with KFP
[17]. The tMFA mathematical equations are quadratic
on the fluxes and the transient parameter. The KFP
equations are convolutions of exponential functions,
they are more difficult to solve, and they require more
input time points. On the other hand, more time points
imply better estimates, and therefore, KFP remains the
gold standard. We propose the use of tMFA in high-
throughput applications and/or when the budget is limited.
Notably using tMFA, we demonstrate that MTX treat-
ment results in a cascade of metabolic changes that are
not simply a consequence of the reduction in the total
purine pool. MTX also induces an increase in the AMP/
ATP ratio, activation of the energy sensor AMPK, inhib-
ition of energy consuming reactions such as protein and
glutathione synthesis, and induction of serine synthesis.
We also show that methionine and thymidylate synthe-
ses are minor contributions to the balance of one-
carbon units.
Pharmacological AMPK activation with the AICAR
riboside has been reported to be synergistic with MTX
treatment [26]. The proposed mechanism is accumulation
of the AMP mimetic ZMP due to inhibition of purine syn-
thesis by MTX. Indeed, MTX induces a significant in-
crease in the ZMP levels in breast cancer cells sensitive to
MTX. We also observe a significant increase in the AMP/
ATP ratio in breast cancer cells sensitive to MTX treat-
ment, in agreement with our previous report for a prostate
cancer cell line [7]. We therefore propose that the increase
of both the ZMP levels and the AMP/ATP ratio contrib-
utes to the AMPK activation due to MTX treatment.
The applications of tMFA go beyond what is presented
above. The same methodology can be applied to quantify
Figure 8 Balance of serine, glycine, and methionine: excess production (positive) or consumption (negative) flux for serine (a), glycine (b), and
methionine (c) relative to their demand for protein synthesis, in untreated (open bars) and MTX-treated (filled bars) cells.
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pyrimidine metabolism using a tracer that labels pyrimi-
dine precursors. tMFA can be used to quantify the bio-
synthetic needs for glutamate and glutamine (proteins,
purines, pyrimidines, glutathione, cysteine exchange). We
therefore anticipate its use in the investigation of glutam-
ine/glutamate metabolism. We also envision the application
of tMFA to interrogate fatty acid metabolism, exploiting
the transient time scale separation between AcCoA and
fatty acids.
Additional file
Additional file 1: Supplementary methods and supplementary
figures.
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